tgfbi expanded nk cells
Cell therapyexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05634369)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07144384 | Early Phase 1 (Phase 1) | Oct 16, 2025 | Ohio State University |
| NCT06203912 | Phase 1 | Mar 5, 2024 | Ohio State University, Sanofi |
| NCT05887882 | Phase 1 | Jan 15, 2024 | CureSearch, Ohio State University, University of California, San Francisco, Washington University in St. Louis |
| NCT06026657 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Ohio State University |
| NCT05634369 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | Ohio State University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ohio State University | Academic/Hospital | 5 | 4 | 2 | 2022 |
| CureSearch | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Sanofi | For profit | 1 | 0 | 1 | 2024 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1